NASDAQ:RIGL - Rigel Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.18 -0.01 (-0.31 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$3.18
Today's Range$3.0150 - $3.28
52-Week Range$2.14 - $4.71
Volume7.34 million shs
Average Volume3.22 million shs
Market Capitalization$521.82 million
P/E Ratio-5.13
Dividend YieldN/A
Beta1.36
Rigel Pharmaceuticals logoRigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and immunoglobulin a nephropathy. Rigel Pharmaceuticals, Inc. has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; BMS for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases. The company was incorporated in 1996 and is based in South San Francisco, California.

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100

Debt

Debt-to-Equity RatioN/A
Current Ratio5.14
Quick Ratio5.14

Price-To-Earnings

Trailing P/E Ratio-5.13
Forward P/E Ratio-4.89
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.48 million
Price / Sales116.11
Cash FlowN/A
Price / CashN/A
Book Value$0.69 per share
Price / Book4.61

Profitability

EPS (Most Recent Fiscal Year)($0.62)
Net Income$-77,990,000.00
Net MarginsN/A
Return on Equity-113.73%
Return on Assets-92.96%

Miscellaneous

Employees103
Outstanding Shares163,580,000

The Truth About Cryptocurrencies

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.17). During the same quarter in the prior year, the business posted ($0.13) earnings per share. View Rigel Pharmaceuticals' Earnings History.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Rigel Pharmaceuticals.

What price target have analysts set for RIGL?

5 Wall Street analysts have issued 12-month target prices for Rigel Pharmaceuticals' shares. Their forecasts range from $7.00 to $10.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $8.30 in the next twelve months. View Analyst Ratings for Rigel Pharmaceuticals.

What are Wall Street analysts saying about Rigel Pharmaceuticals stock?

Here are some recent quotes from research analysts about Rigel Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year. The Company's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. We have product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia, and asthma and allergy, as well as in cancer. " (5/9/2018)
  • 2. Cantor Fitzgerald analysts commented, "Premature to Write-off IgAN for Now. Given the totality of the data and unmet need in IgAN, we have slightly lowered our probability of success for the program. While the data did not meet the primary endpoint of a statistically significant mean change in proteinuria from baseline, several positive trends were found among a pre-specified population of patients with greater than 1,000mg/g of proteinuria. Treatment with 150mg fostamatinib twice daily at 24-weeks led to a median reduction in proteinuria from baseline of 803mg/ g (n=15), compared with 100mg fostamatinib’s reduction of 720mg/g (n=16) and placebo’s reduction of 177mg/g (n=14). These trends were also observed among patients who entered the study with a baseline proteinuria of 2,000mg/g. During the study safety events were in-line with previous experiences, with two patients experiencing severe adverse events across each cohort and two events reported as drug related (pancreatitis and abnormal liver enzyme). As a reminder, fostamatinib has over 5,000 patient-years of experience generated with the drug. Going forward, Rigel plans to advance the IgAN program through collaborations with a pharmaceutical partner, which we believe could be potentially bundled with an ex-U.S. territory licensing of TAVLISSE for lead indication ITP." (4/3/2018)

Who are some of Rigel Pharmaceuticals' key competitors?

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the folowing people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 57)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 53)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 59)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Thomas A. Raffin, Co-Founder (Age 71)

Has Rigel Pharmaceuticals been receiving favorable news coverage?

News articles about RIGL stock have been trending somewhat positive on Saturday, according to Accern. Accern identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rigel Pharmaceuticals earned a coverage optimism score of 0.06 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 45.40 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.77%), Palo Alto Investors LP (2.42%), Rock Springs Capital Management LP (1.57%), JPMorgan Chase & Co. (1.24%), Northern Trust Corp (1.09%) and Candriam Luxembourg S.C.A. (0.92%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Donald G Payan and Ryan D Maynard. View Institutional Ownership Trends for Rigel Pharmaceuticals.

Which institutional investors are selling Rigel Pharmaceuticals stock?

RIGL stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., DAFNA Capital Management LLC and Teacher Retirement System of Texas. Company insiders that have sold Rigel Pharmaceuticals company stock in the last year include Anne-Marie Duliege and Ryan D Maynard. View Insider Buying and Selling for Rigel Pharmaceuticals.

Which institutional investors are buying Rigel Pharmaceuticals stock?

RIGL stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Allianz Asset Management GmbH, Allianz Asset Management GmbH, Candriam Luxembourg S.C.A., UBS Group AG, Rock Springs Capital Management LP, A.R.T. Advisors LLC and DekaBank Deutsche Girozentrale. View Insider Buying and Selling for Rigel Pharmaceuticals.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $3.18.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $521.82 million and generates $4.48 million in revenue each year. The biotechnology company earns $-77,990,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. Rigel Pharmaceuticals employs 103 workers across the globe.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]


MarketBeat Community Rating for Rigel Pharmaceuticals (RIGL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  436
MarketBeat's community ratings are surveys of what our community members think about Rigel Pharmaceuticals and other stocks. Vote "Outperform" if you believe RIGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RIGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.